{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:06:42Z","timestamp":1789229202774,"version":"build-2803163510"},"reference-count":63,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":815,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[1999,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Treatment options for allergic rhinitis include antihistamines, decongestants, anticholinergics, cromolyn sodium and corticosteroids. As the nose is a small organ, comprising less than 1% of total body mass and surface area, it seems logical to confine treatment of rhinitis to the diseased organ.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the effects of therapy with intranasal fluticasone propionate (FP), both on subjective symptoms and pathophysiological mechanisms, in rhinitis patients during pollen season when the patients were symptomatic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used a double\u2010blind, placebo (PLA)\u2010controlled, randomized, double dummy, parallel group study of the effect of 6 weeks treatment. The double\u2010blind comparison was made between the following three treatments: FP aqueous nasal spray, 200\u2003\u03bcg taken once daily, levocabastine (LEV) nasal spray, 200\u2003\u03bcg taken twice daily and PLA nasal spray. Clinical evaluation and the levels of cells and mediators in nasal washing were performed before and after treatments. Twenty\u2010four patients (11 men and 13 women, aged 17\u201350 years, mean age 30.1\u2003\u00b1\u20038.5) with strictly seasonal allergic rhinitis to Parietaria entered the study. Clinical evaluation and the levels of inflammatory cells (eosinophils and activated eosinophils, i.e. EG<jats:sub>2<\/jats:sub><jats:sup>+<\/jats:sup>) and their mediators (tryptase, eosinophil cationic protein, eosinophil protein X and neutrophil myeloperoxidase) in nasal\u2010lavage were performed before and after treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment with FP significantly increased, with respect to placebo, the percentage of days without sneezing (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001), nasal blockage (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001), rhinorrhea (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001), nasal itching (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). Furthermore, treatment with FP showed additional benefits with respect to LEV. The percentage of days without nasal blockage was significantly higher in the FP group that in the placebo group (<jats:italic>P<\/jats:italic>\u2003=\u20030.018). The same applied to rhinorrhea (<jats:italic>P<\/jats:italic>\u2003=\u20030.009). The percentages of days without sneezing and itching were instead not significantly different between the two groups. As expected, no significant differences were observed in baseline medians of the rhinitis symptom scores as well as in mean values of all mediators and eosinophils in nasal lavages of the various groups under study. After treatment the mean of subjective symptoms as well as all values in nasal lavage level fell significantly only in the FP group, whereas no significant changes were observed either in LEV or PLA groups. Accordingly, significant differences were observed at the end of the treatments between the values of fluticasone group vs LEV and PLA group values. Significant correlations between these values and symptom scores were found, according with literature data suggesting a pathogenetic role for these mediators and eosinophils in rhinitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>FP (200\u2003\u03bcg once daily) affords a significant degree of improvement in rhinitis control during pollen season, as measured by subjective and objective parameters, compared with LEV (200\u2003\u03bcg twice daily) and PLA. The therapeutic benefits of intranasal FP are reflected in, and may be caused by, the decrease in nasal inflammatory cells.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2222.1999.00643.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T09:35:32Z","timestamp":1047375332000},"page":"1367-1377","source":"Crossref","is-referenced-by-count":27,"title":["Comparison of the effects of fluticasone propionate, aqueous nasal spray and levocabastine on inflammatory cells in nasal lavage and clinical activity during the pollen season in seasonal rhinitics"],"prefix":"10.1111","volume":"29","author":[{"family":"Di Lorenzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Gervasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Esposito Pellitteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Di Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Potestio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Candore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Mansueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1164\/ajrccm\/142.2.434","article-title":"Mucosal inflammation in asthma. State of the art","volume":"142","author":"Djukanovic R","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_6_3_2","unstructured":"CreticosPS. Allergic rhinitis. In: Busse WW Holgate ST eds. Asthma and Rhinitis. Oxford: Blackwell Science Ltd 1995:1394414."},{"issue":"19","key":"e_1_2_6_4_2","first-page":"1","volume":"49","author":"International Consensus Report on the diagnosis and Management of Rhinitis","year":"1994","journal-title":"Allergy"},{"key":"e_1_2_6_5_2","first-page":"597","article-title":"Mediators release after nasal airway challenge with allergen","volume":"128","author":"Naclerio RM","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_6_6_2","first-page":"226","article-title":"Mediators of human mast cells and human mast cell subsets","volume":"58","author":"Schwartz LB","year":"1987","journal-title":"Ann Allergy"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(90)90064-B"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1993.tb00688.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000236855"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70288-9"},{"key":"e_1_2_6_11_2","first-page":"474","article-title":"Pharmacotherapy of allergic rhinitis","volume":"8","author":"Delafuente JC","year":"1989","journal-title":"Clin Pharm"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1993.tb00755.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1994.tb00818.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1996.tb00653.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02736.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016487609120899"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80017-X"},{"key":"e_1_2_6_18_2","first-page":"433","article-title":"Mechanism of action of some commonly used nasal drugs","volume":"107","author":"Jackson RT","year":"1992","journal-title":"Otolaryngol Head Neck Surg"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2500\/108854196779165021"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00049-Q"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(88)90198-4"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80005-3"},{"key":"e_1_2_6_23_2","article-title":"Intranasal fluticasone propionate is more effective than astemizolo for seasonal allergic rhinitis [Abstract]","volume":"72","author":"Strickel W","year":"1994","journal-title":"Ann Allergy"},{"key":"e_1_2_6_24_2","first-page":"298","article-title":"Intranasal fluticasone propionate reduces histamine tryptase in the mucosa of allergic rhinitis patients [Abstract]","volume":"91","author":"Meltzer EO","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0954-6111(95)90259-7"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1994.00420230086010"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)80065-0"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb01027.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70303-2"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90178-3"},{"key":"e_1_2_6_31_2","first-page":"A980","article-title":"on behalf of FLNC02 Study Group. Fluticasone propionate aqueous nasal spray once daily nasal LEV twice daily vs nasal PLA in the treatment of seasonal rhinitis","volume":"155","author":"Ortolani C","year":"1997","journal-title":"Am J Resp Crit Care Med"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1998.tb03932.x"},{"key":"e_1_2_6_33_2","first-page":"89","article-title":"Daily variation patterns of airborne allergenic pollen in southwestern Spain","volume":"8","author":"Gonzalez Minero FJ","year":"1998","journal-title":"J Invest Allergol Clin Immunol"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.2500\/108854196778662381"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1992.tb00661.x"},{"key":"e_1_2_6_36_2","unstructured":"AccorsiCA Bandini MazzantiM RomanoB FrenguelliG MincigrucciG. Allergenic Pollen: Morphology and Microscopic Photographs. In: D'amato G Spieksma FTM Bonini S eds. Allergenic Pollen and Pollinosis in Europe1991:2435."},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90485-5"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1997.tb01257.x"},{"key":"e_1_2_6_39_2","first-page":"1","article-title":"Position paper of the Subcommittee on Skin tests used in type I allergy testing","volume":"10","author":"European Academy of Allergology and Clinical Immunology","year":"1989","journal-title":"Allergy"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)70281-1"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(89)90191-9"},{"key":"e_1_2_6_42_2","first-page":"139","article-title":"Flow cytometric evaluation of activated blood eosinophils in immunoallergic diseases","volume":"50","author":"Rumi C","year":"1995","journal-title":"Allergy"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1996.tb00652.x"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1996.tb00659.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02734.x"},{"key":"e_1_2_6_46_2","first-page":"261","article-title":"Effect of topical levocabastine on nasal response to allergen challenge and nasal hyperreactivity in perennial rhinitis","volume":"75","author":"De Graaf\u2010in'T Veld T","year":"1995","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_2_6_47_2","first-page":"S35","article-title":"Importance of ECP in monitoring allergic respiratory inflammation","volume":"10","author":"Di Lorenzo G","year":"1997","journal-title":"Int J Immunopathol Pharmacol"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02733.x"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1993.tb04697.x"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02737.x"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)01182-1"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)01187-0"},{"key":"e_1_2_6_53_2","first-page":"237","article-title":"Nasal response to allergen challenge in patients with immediate asthmatic reaction","volume":"24","author":"Palczynsky C","year":"1996","journal-title":"Allergol Immunopathol (Madr)"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1996.tb00653.x"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90333-6"},{"issue":"6","key":"e_1_2_6_56_2","first-page":"430","article-title":"Are blood eosinophil number and activity important for the development of late asthmatic reaction after allergen challenge?","volume":"2","author":"Venge P","year":"1989","journal-title":"Eur Respir J"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.4.7921442"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447020-00007"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1996.tb00654.x"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02735.x"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02738.x"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1998.00239.x"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.6.7767538"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1995.tb00399.x"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2222.1999.00643.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2222.1999.00643.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2222.1999.00643.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T13:03:53Z","timestamp":1698498233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2222.1999.00643.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["10.1046\/j.1365-2222.1999.00643.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2222.1999.00643.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10]]}}}